Startup profile · funding coverage
GC Therapeutics
Cell-therapy biotech using George Church–originated iPSC programming platform TFome.
Stage
series a
Status
private
Coverage
full
Why GC Therapeutics is interesting
GC Therapeutics targets scalable off-the-shelf cell therapies; a16z Bio + Health joined Pear VC in its $65M Series A launch round.
Key facts
- Series A (2024): $65M led by Cormorant Asset Management with a16z Bio + Health (/fund/andreessen-horowitz) and Pear VC (/fund/pear-vc) (BusinessWire)
- TFome platform originated from George Church's lab at Harvard; targets scalable off-the-shelf iPSC cell therapies
Investors in our directory
Funds linked from GC Therapeutics's profile — open a fund page for stage focus and related deal articles.
Industries
Biotech & Life Sciences
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
Related funding articles
Venture Capital Tracker pieces that cover GC Therapeutics's financing or category context.
FAQs about GC Therapeutics
Funding context and why this company shows up in venture coverage.
GC Therapeutics develops off-the-shelf cell therapies using TFome, a proprietary induced pluripotent stem cell (iPSC) programming platform. The goal is consistent, scalable cell products for regenerative medicine.
GC Therapeutics' $65M Series A (2024) was led by Cormorant Asset Management with Andreessen Horowitz (/fund/andreessen-horowitz) Bio + Health and Pear VC (/fund/pear-vc) participating.
GC Therapeutics is at Series A based on its 2024 $65M launch round.
Autologous cell therapies are expensive and hard to scale. GC Therapeutics targets off-the-shelf iPSC products using a programming platform from George Church's lab — a bet on manufacturing consistency.
No. GC Therapeutics remains a private company.
Last updated: 2026-07-24